Publication

FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models

Scientific Reports 2022 12(1):15661, 2022

O’Farrell M, Duke G, Crowley R, Buckley D, Martins EB, Bhattacharya D, Friedman SL, Kemble G

Share this page

Resource Library

Related resources

Metabolic, biochemical, histopathological, and transcriptomic effects of Seladelpar in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH

Metabolic, biochemical and histological characterization of a CDAA-HFD-induced non-obese rat model of advanced NASH with progressive fibrosis

Hepatic molecular characteristics of patients with varying degrees of nonalcoholic steatohepatitis compared to healthy normal weight individuals

Metabolic and hepatic effects of liraglutide, obeticholic acid and elafbranor in diet-induced obese mouse models of biopsy-confrmed nonalcoholic steatohepatitis

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 2650